Hosted on MSN3d
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study
Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in ...
pharmaphorum3d
MSD gets first positive trial of Keytruda/Lynparza combo
"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...
FiercePharma4d
Merck gets rare win with Keytruda-Lynparza combo but role of Keytruda in ovarian cancer 'remains uncertain'
Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. | Merck hasn’t had much luck ...
GlobalData on MSN3d
MSD’s trial of combination therapy for ovarian cancer meets primary endpoint
US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ...
Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer
Merck's ovarian cancer trial met its primary endpoint, while lymphoma trial data set the Phase 3 dose for zilovertamab ...
healthandpharma4d
Breakthrough in First-Line Ovarian Cancer Treatment: KEYTRUDA and LYNPARZA
Merck has announced that the Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) combined with chemotherapy ...
Daily2d
Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival in Patients With Advanced Epithelial Ovarian Cancer: Merck
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial ...
Merck says Phase 3 KEYLYNK-001 trial met primary endpoint
Merck (MRK) announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA plus chemotherapy followed by maintenance with LYNPARZA, with or ...
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced ...
Yahoo Finance4d
Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer
The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza (olaparib), with or without bevacizumab, as a first-line treatment for BRCA non-mutated ...
Pharmabiz3d
Merck announces phase 3 KEYLYNK-001 trial meets primary endpoint of PFS in patients with advanced epithelial ovarian cancer
Merck announces phase 3 KEYLYNK-001 trial meets primary endpoint of PFS in patients with advanced epithelial ovarian cancer: Rahway, New Jersey Tuesday, December 10, 2024, 18:00 H ...